Tuesday 26 September
07.30-09.00 EDUCATIONAL TRACK SESSION 3 : ABOVE AND BELOW THE DIAPHRAGM
CHAIRS: Jim Egan, Dublin, Ireland
Annemarie Weissenbacher, Oxford, United Kingdom
07.45 Old and new listing criteria for lung and heart transplantation
John Dark, Newcastle, United Kingdom
08.00 Old and new listing criteria for liver, pancreas and intestinal transplantation
Peter Friend, Oxford, United Kingdom
08.15 How do factors from above the diaphragm impact on the outcome of transplantation of organs below the diaphragm?
Stephan Eschertzhuber, Innsbruck, Austria
08.30 Combined transplanted patients - Which organ drives the immunosuppressive regimen?
Nassim Kamar, Toulouse, France
07.30-09.00 EDUCATIONAL TRACK SESSION 4 : PATHOPHYSIOLOGY AND ENDPOINTS ON TOLERANCE
CHAIRS: Cristina Cuturi, Nantes, France
Nina Pilat, Vienna, Austria
07.45 Clinical tolerance studies
Megan Sykes, New York, United States
08.00 Endpoints and biomarkers for clinical tolerance
Birgit Sawitzki, Berlin, Germany
08.15 Macrophages and the induction of tolerance
Jordi Orchando, New York, United States
08.30 T-reg induced allograft tolerance in human
Giovanna Lombardi, London, United Kingdom
08.00-09.00 Full oral sessions
Brief oral sessions
09:10 - 10:40 STATE OF THE ART 4 | NEW CONCEPTS IN TRANSPLANT INFECTIOUS DISEASES: MICROBIOTA, AND BEYOND
New tools have allowed an unprecedented genetic insight into the composition of our microbiota and our virome. First, we explore the role of the virome and microbiota as it relates to transplantation including potential clinical applications. We aim to elaborate on the impact in transplantation on an individual and epidemiological level. The immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. The new anti-HCV drugs have made eradication of HCV in virtually all patients a realistic goal, but how important is a complete control of viral replication in the context of HCV and other viruses?
CREATED BY: Marina Berenguer, Valencia, Spain
Nicolas Müller, Zurich, Switzerland
CHAIRS: Maria Luisa Alegre, Chicago, United States
Marina Berenguer, Valencia, Spain
09.10 Transkingdom interplay - the complex interactive world of the microbiome
Wang Dave, St. Louis, United States
09.30 Knowledge and clinical applications of microbiota in transplantation
Frederick Bushman, Philadelphia, United States
09.50 Viruses and the recipient immune response: relevant crosstalk in transplantation
Oriol Manuel, Lausanne, Switzerland
10.10 The impact of HCV treatment on liver transplantation
Michael R. Charlton, Salt Lake City, United States
09:10 - 10:40 STATE OF THE ART 5 | CELL THERAPY IN CLINICAL TRIALS
Cell therapy may be a suitable adjunct to conventional immunosuppression. Despite a major enthusiasm, however, major issues emerged in the first clinical applications. The question now is: how can technical and regulatory hurdles be overcome within a reasonable time frame? Will cell therapy ever be commercially interesting and will its implementation enhance solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy tomorrow and in 10 years.
CREATED BY: Pietro Cippà, Zurich, Switzerland
Marc Dahlke, Regensburg, Germany
CHAIRS: Marc Dahlke, Regensburg, Germany
Thomas Wekerle, Vienna, Austria
09.10 Technical and regulatory issues. From the idea to the clinical application
Marlies Reinders, Leiden, The Netherlands
09.30 Sharing clinical experience. What can we learn from hematologists?
Francesco Dazzi, London, United Kingdom
09.50 Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
Suzanne T. Ilstad, Louisville, United States
10.10 The future: Clinical applications of stem cells in the context of transplantation vs. regeneration?
Martin Johannes Hoogduijn, Rotterdam, The Netherlands
09:10 - 10:40 STATE OF THE ART 6 | ONE FOR ALL OR ALL FOR ONE; MOVING AWAY FROM PROTOCOLIZED MEDICINE
The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall outcome in transplantation. It is increasingly recognized though, that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone’s lips. This session aims to confront the reality by focusing on four important topics in the field.
CREATED BY: Georg Böhmig, Vienna, Austria
Nicolas Müller, Zurich, Switzerland
CHAIRS: Georg Böhmig, Vienna, Austria
Nicolas Müller, Zurich, Switzerland
09.10 Is transplantation ready for systems medicine?
Rainer Oberbauer, Vienna, Austria
09.30 Individualized antimicrobial prophylaxis
Jay Alan Fishman, Boston, United States
09.50 Phenotypic diversity of rejection and allograft dysfunction
Phil Halloran, Edmonton, Canada
10.10 Tailored immunosuppression
Christian Hugo, Dresden, Germany
11.10-12.40 ASIA LEADING THE WAY (Joint Session with the Asian Society for Transplantation)
This session was jointly organized with the Asian Society for Transplantation and aims to highlight some of the significant advancements in transplantation achieved in the recent past. We are proud to bring to your attention, programs and topics with significant thrive from our partners in Asia.
CHAIRS: Jan Lerut, Brussels, Belgium
Dennis Serrano, Quezon City, Philippines
11.20 Tissue Repair and its Relevance to Transplantation
Nathaniel S. Hwang, Seoul, Korea
11.40 Challenges in Increasing Organ Donation in Asia
Romina Danguilan, Manila, Philippines
12.00 ABO Incompatible Kidney Transplantation: Future Directions
Shiro Takahara, Osaka, Japan
12.20 State of the Art of Living Donor Liver Transplantation
Chao Long Chen, Kaohsiung City, Taiwan
11.10-12.40 BIG BANG 3 | INNOVATION IN IMMUNOMEDICATION: THE MODERN PROMETHEUS
Putting their feet in those of Dr Frankenstein, scientists have started stitching disparate biological pieces to create new therapeutic opportunities. far from sci-fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionize solid organ transplantation will be scrutinized during this Big Bang session.
CREATED BY: Josep Maria Grinyó, Barcelona, Spain
Olivier Thaunat, Lyon, France
CHAIRS: Julien Zuber, Paris, France
11.10 Deciphering and targeting protein-protein interactions: a new challenge in biomedicine
Juan Fernández Recio, Barcelona, Spain
11.30 The potential of bispecific antibodies
11.50 Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor
Megan Levings, Vancouver, Canada
12.10 Systems biology applications for prognostication and therapeutics
Patrick Aloy, Barcelona, Spain
11.10-12.40 Full oral sessions
Elevator Pitch sessions
13.00-14.00 Corporate Parallel lunch Symposia
Brief oral sessions
13.00-14.00 SURROGATE ENDPOINTS INTERNATIONAL WORKSHOP
Drug development in transplantation has diminished due to the lack of fitting endpoints, the long timespan between transplantation and graft failure and the low rates of early rejection. At the same time, we find patients suffering from long-term graft loss. Hence it is paramount to establish new principles to allow development of novel therapeutics to treat and prevent this from happening. One of the main objectives in our thrive to address this is to identify and validate surrogate markers for long-term graft outcome and identify novel endpoints for trials and drug development. The field of transplantation is facing one of the greatest challenges hindering further advancement of this field and all individuals and institutions involved in this field need to work together to prevail.
In this interactive session, we will discuss the need for new endpoints in the field of transplantation, the potential and problems with histology, the applicability of donor-specific antibodies, and the promise of combined calculated markers as surrogate endpoints. We will discuss the progress that has and can be achieved by transplant societies and health authorities. The session will focus on kidney transplantation, although the methodology and conclusions are likely valid also for other organs.
CREATED BY: Maarten Naesens, Leuven, Belgium
Stefan Schneeberger, Innsbruck, Austria
CHAIRS: Maarten Naesens, Leuven, Belgium
Stefan Schneeberger, Innsbruck, Austria
13.00 Why do we need new endpoints
Mark Stegall, Rochester, United States
13.10 The potential of combined calculated surrogate endpoints
Alexandre Loupy, Paris, France
13.22 The difficult but important place of histology as endpoint
Maarten Naesens, Leuven, Belgium
13.34 DSAs as surrogate endpoint for drug development
Peter Nickerson, Winnipeg, Canada TBC
13.46 Panel discussion
14:05-15:35 PLENARY SESSION 3 | INNOVATION UNDER PRESSURE: TRANSPLANT PATIENT CARE IN 2020
Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challenging than ever. While novel technologies may help to effectively monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.
CREATED BY: Marina Berenguer, Valencia, Spain
Antonio Roman, Barcelona, Spain
CHAIRS: John Forsythe, Edinburgh, United Kingdom
Christophe Legendre, Paris, France
14.05 Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others
Wei-Ping Andrew Lee, Baltimore, United States
14.25 Beyond survival: quality of life after transplantation
Lianne Singer, Toronto, Canada
14.45 New tech for new patients: digital communication and self-monitoring
Magali Giral, Nantes, France
15.05 New models for patient care: wish for what you care for
Marcel Levi, London, United Kingdom
16.00-17.00 BIG BANG 4 | AGEING AND IMMORTALITY
In this session, we discuss the changing demographics of donors and recipients and its impact on transplantation in reference to organ quality, ischemia-reperfusion injury and immunosenescence. In addition, the biology of ageing and the concept of accelerated ageing after transplantation with its implications on the fate of the graft and the patient are being addressed. As a consequence of the changing demographics, transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. Finally, we will evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.
CREATED BY: Maarten Naesens, Leuven, Belgium
Olivier Thaunat, Lyon, France
CHAIRS: Maarten Naesens, Leuven, Belgium
16.00 Older graft, older recipients, young ideas
Stefan Tullius, Boston , United States
16.20 Accelerated ageing after transplantation
Peter Stenvinkel, Stockholm, Sweden
16.40 Halting aging: the science of rejuvenation
Brian Kennedy, Novato, United States
16.00-17.00 Brief oral sessions
16.00-17.00 THE DEVIL'S ADVOCATE: CONTRADICTORY DISCUSSION OF CLINICAL SCIENCE
The format of this session will be the presentation of the article by the author followed by a critical discussion by the “opponent” and a rebuttal and general discussion with the audience. It will be a highly interactive session.
CREATED BY: Rainer Oberbauer, Vienna, Austria
Josep Maria Grinyó, Barcelona, Spain
CHAIRS: Rainer Oberbauer, Vienna, Austria
Josep Maria Grinyó, Barcelona, Spain
Ethical debate
Allocating Organs to Cognitively Impaired Patients.
Scott D. Halpern, M.D., Ph.D., and David Goldberg, M.D., M.S.C.E. N Engl J Med 2017; 376:299-301January 26, 2017DOI: 10.1056/NEJMp1613858
16:00 Defender: Scott Halpern, United States
16:20 Opponent: Michael Bos, Leiden, The Netherlands
16:30 Discussion
Expensive but useless?
Clinical value of C1q assay in antibody-mediated rejection
Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Wiebe, Gareau, Pochinco, Gibson, Ho, Birk, Blydt-Hansen, Karpinski, Goldberg, Storsley, Rush, Nickerson. Am J Transplant. 2017 Mar;17(3):703-711. doi: 10.1111/ajt.14015. Epub 2016 Oct 3.
16:40 Defender: Peter Nickerson, Winnipeg, Canada
16:50 Opponent: Denis Glotz, Paris, France
17:00 Discussion
17.00-18.30 Corporate Plenary/Parallel Symposium
Full oral sessions
18.30-19.30 ESOT General Assembly
Elevator Pitch sessions
Brief oral sessions